| | | June 14, 2022 Hey traders! It's Michael here with the BRAND NEW Stock Dork Premarket Report, your go-to guide for the day's biggest trading news and hottest premarket stocks! Today is Tuesday, June 14th. Let's get ready to trade! |
| The S&P 500 sold-off for 3.9% on Monday and officially entered bear market territory as a result of the losses. The Nasdaq fared even worse, losing 4.7% on the session, while the Dow fell 2.8%, and the small-cap Russell 2K tumbled 4.8%. Today, futures are pointing to a slight rebound at the opening bell. S&P 500 contracts are currently showing a 0.5% gain. Oracle Corp [ORCL] - Last Close: $64.05 Oracle is on the rise after a strong earnings report. The enterprise tech firm reported Q4 sales of $11.84 billion, beating the Street's $11.65 billion estimate, and generated adjusted earnings of $1.54 per share, which also beat the consensus EPS forecast of $1.38. Oracle's CEO reported "strong demand" for its cloud services and noted several other bullish business updates in its Q4 earnings conference call. ORCL's double-line earnings beat is powering the stock to a 12.0% gain on active premarket trading volume. Our Take: Oracle could be a promising value play in today's chaotic market. The company has a stable business model, and share prices are down big from their 52-week highs. This breakout quarter could mark a pivot point for the stock. National Vision Holdings [EYE] - Last Close: $25.28 National Vision Holdings is set to join a major index, and shares are rallying. The US optical retailer is set to replace Renewable Energy Group in the S&P SmallCap 600 prior to Thursday's opening bell. REGI was recently acquired by Chevron Corp in a deal that officially closed today, creating a vacancy which National Vision Holdings is expected to fill. EYE is showing a 13.8% gain on active trading volume in today's premarket. Our Take:EYE could see a sharp influx of buying volume as index fund managers acquire shares in order to rebalance their holdings, although it's unclear how much of that is already priced into the stock. Regardless, joining the S&P SmallCap 600 could be a sign of good things to come for this up-and-coming retailer. Kaival Brands Innovations Group [KAVL] - Last Close: $1.73 Kaival Brands just landed a big deal with a major partner. The Florida-based company landed a deal with Philip Morris International's wholly-owned affiliate Philip Morris Products S.A. (PMPSA) for the development and distribution of electronic nicotine delivery system (ENDS) products in markets outside the US, subject to market and/or regulatory assessment. Under the terms of the deal, PMPSA receives a license that will allow it to manufacture, promote, sell, and distribute the BIDI® Stick, an ENDS system from Kaival subsidiary Bidi Vapor. Financial details of the arrangement were not immediately disclosed, but Kaival said adding PMI's vast portfolio of retail partners to its portfolio could create a substantial new revenue stream. KAVL is up 56.5% on active premarket trading volume. Our Take: Philip Morris is a powerful partner, so this could be a landmark deal for Kaival Brands. However, it'll be hard to gauge the deal's ultimate impact until we know more about it impacts Kaival's sales growth and earnings. Soleno Therapeutics [SLNO] - Last Close: $0.1702 A new clinical data release is rallying shares of Soleno Therapeutics. After Monday's close, the clinical-stage biotech firm presented upbeat clinical data from ongoing late-stage DCCR development program for the treatment of Prader-Willi syndrome (PWS) at an industry conference in Atlanta. The data revealed positive responses in PWS patients following one year of treatment with DCCR. The patients were treated in C601, a Phase 3 randomized, double-blind, placebo-controlled study and C602, its ongoing open-label extension. Soleno said patients experienced noteworthy metabolic and body composition improvements as a result of the treatments. SLNO is this morning's most active premarket stock, and it's up 35.1%. Our Take: SLNO is definitely a speculative trade, but it could pay off big if the company gets its PWS treatment to market. This long-shot biotech stock could have potential if it all pans out. |
| Gainers Clovis Oncology [CLVS] >> +33.7% G Medical [GMVD] >> +12.8% Embark Technology [EMBK] >> +25.7% Decliners Redbox Entertainment [RDBX] >> (21.3%) SeaChange [SEAC] >> (35.3%) OutSet Medical [OM] >> (21.9%) Sprinklr [CXM] ... PM ReNew Energy Global [RNW] ... PM Tuya [TUYA] ... PM IronNet [IRNT] ... PM Core & Main [CNM] ... PM |
| NFIB Small Business Index [May] ... 6a Producer Price Index Final Demand [May] ... 8:30a |
| Thanks for reading! Don't forget, I'm always eager to hear from you. Reply to this email with your questions, comments, or general feedback, and I'll get back to you as soon as I can. Wishing you big returns on your investments this week, as always! - Michael "The Stock Dork" Taylor P.S. Want My Alerts Delivered To Your Cell Phone? Sign up for mobile alerts and get the latest updates delivered to your cell. Disclaimer © 2022 TheStockDork.com. All rights reserved. This message was sent by TheStockDork.com and may contain commercial elements such as advertising. Read full terms here. |
|
|
|
| | |
|
